Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
76.86 CHF | -1.00% | -0.77% | -.--% |
05-16 | Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15 | DP |
05-16 | Novartis: presents results of tender offer for MorphoSysy | CF |
Sales 2024 * | 48.92B 44.46B 3,852B | Sales 2025 * | 50.86B 46.21B 4,004B | Capitalization | 210B 191B 16,528B |
---|---|---|---|---|---|
Net income 2024 * | 10.42B 9.47B 821B | Net income 2025 * | 11.92B 10.83B 938B | EV / Sales 2024 * | 4.54 x |
Net Debt 2024 * | 12.44B 11.3B 979B | Net Debt 2025 * | 11.34B 10.31B 893B | EV / Sales 2025 * | 4.35 x |
P/E ratio 2024 * |
20.1
x | P/E ratio 2025 * |
17.2
x | Employees | - |
Yield 2024 * |
3.51% | Yield 2025 * |
3.64% | Free-Float | 85.22% |
Latest transcript on Novartis AG
1 week | -0.77% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 31/12/04 | |
Director of Finance/CFO | 59 | 31/12/02 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 15/05/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 31/12/12 |
Simon Moroney
BRD | Director/Board Member | 65 | 27/02/20 |
Chairman | 68 | 31/12/12 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+8.49% | 168B | |
-0.52% | 162B |
- Stock Market
- Equities
- NOVN Stock
- 0QM7 Stock